Overview

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

Status:
Completed

Trial end date:
2012-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib after an autologous peripheral blood stem cell transplant may stop the growth of any cancer cells that remain after transplant. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib in treating patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant.

Phase:

Phase 1

Details

Lead Sponsor:

Barbara Ann Karmanos Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Bortezomib